Bizarre nuclear features in a smooth muscle tumor raise this somewhat important differential. Histology helps, and IHC may be needed.
Study the digital slides here: https://dpa-dapa.com/#/public/....presentation/display
Please share this with others who may be interested, and subscribe to the channel so you will receive notice as new videos are uploaded.
You can reach out to me directly via:
Facebook: Lewis Hassell
Twitter: @HassellLewis
or by email at lewis-hassell@ouhsc.edu
More good content available at my public, pathology-focused Facebook group: Phat Trien GPB VN
Thanks for joining me!

For this week’s #KidneyCANDID, we caught up with Dr. Marston Linehan from NCI at last week’s DF/HCC SPORE Advisory Meeting in Boston.

Dr. Linehan pioneered the study of the genetic basis of kidney cancer. His team identified the genes for the common forms of kidney cancer and described the pathways of these kidney cancer genes. His recent studies targeting the metabolic basis of kidney cancer have resulted in the regression of metastatic cancer in patients with type 1 and type 2 papillary kidney cancer.

Dr. Linehan has a message of hope for patients with kidney cancer … take minute to listen!

Have a KidneyCANDID topic you'd like to see us tackle? Let us know by emailing info@kidneycan.org with KidneyCANDID Topic in the subject line.

—————————————————————————
KidneyCAN works to accelerate cures for kidney cancer by providing patient support and education, encouraging enrollment in clinical trials, advocating for research funding from Congress, and sponsoring collaborative efforts between researchers and medical communities.

To learn more about KidneyCAN: https://kidneycan.org​
Support our work: https://kidneycan.org/donate

In this video we take a closer look at how the FH gene codes for the fumarate hydratase enzyme. All info has been graciously peer-reviewed by Dr. Christian Frezza (https://www.cecad.uni-koeln.de..../research/principal-

Links from the video

3D FH protein - https://www.ncbi.nlm.nih.gov/Structure/icn3d/full.html?&mmdbid=142242&bu=1&showanno=1&source=full-feature

Complete FH genome sequence - https://www.ncbi.nlm.nih.gov/nucleotide/NG_012338.1?report=genbank&log$=nucltop&blast_rank=1&RID=MMEWZH37013

Complete exome sequence (exons) - http://databases.lovd.nl/share....d/refseq/FH_NM_00014

Image sources:
https://commons.wikimedia.org/....wiki/File:Cos-huma-n
https://commons.wikimedia.org/....wiki/File:Eukaryotic
https://cdn.pixabay.com/photo/....2013/07/13/09/58/gen
https://commons.wikimedia.org/....wiki/File:Codon_usag
https://commons.wikimedia.org/....wiki/File:Chromosome
https://upload.wikimedia.org/w....ikipedia/commons/4/4

Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer

CME Available: https://auau.auanet.org/node/29062

Course Director: W. Marston Linehan, MD
Course Faculty: Mark W. Ball, MD; Ramaprasad Srinivasan, MD, PhD; David F. McDermott, MD

Upon completion of this activity, participants will be able to:
1. Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions and outline ways in which knowledge of kidney cancer subtypes can alter surgical approach.
2. Apply advanced strategies for partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach, and methods for renorrhaphy.
3. Describe techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy.
4. Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with advanced disease.
5. Describe new and emerging targeted therapy and immuno-oncology options for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.

This educational activity is supported by independent educational grants from:
Astellas
AstraZeneca
Bristol-Myers Squibb
Genentech
Merck
Pfizer, Inc.
Sanofi Genzyme

Presented At:
Cell Biology Virtual Event 2019

Presented By:
Margaret Hoang, PhD - Senior Scientist, Research & Development, NanoString Technologies, Inc.

Speaker Biography:
Dr. Margaret Hoang is a Senior Scientist and Next-Generation Sequencing (NGS) Technical Lead at Nanostring Technologies. She applies her expertise in Cancer Genomics and NGS in the development of the GeoMx Digital Spatial Profiler (DSP) sequencing readout capability. Prior to Nanostring, she was a Post-doctoral Fellow at Johns Hopkins School of Medicine characterizing mutational signatures induced by environmental mutagens in urothelial cancers. Margaret received her B.S. in Biochemistry from University of Washington and Ph.D. in Biology from Johns Hopkins University.

Co-Presented By:
Maija Kiuru, PhD - Assistant Professor of Clinical Dermatology and Pathology, UC Davis

Speaker Biography:
Dr. Maija Kiuru is a dual board-certified practicing dermatologist and dermatopathologist and a physician-scientist at University of California, Davis. Dr. Kiuru received her MD degree and PhD in medical genetics from the University of Helsinki, Finland. Her thesis on hereditary leiomyomatosis and renal cell cancer (HLRCC) established the association between aggressive renal cell carcinoma, uterine fibroids, and cutaneous leiomyomas and identified the predisposing germline mutation in FH gene. She continued her research training as a postdoctoral fellow at Weill Cornell Medical College and Columbia University in New York. This research culminated in the discovery of PLCD1 mutations in hereditary leukonychia, revealing a new gene in nail biology, and identifying novel stem cell therapies for hereditary skin blistering disorders. Dr. Kiuru received her clinical training in dermatology and dermatopathology at Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center in New York.

Webinar:
Identification of Novel Biomarker Candidates for Early Detection of Melanoma

Webinar Abstract:
Early detection is critical for improved survival in melanoma. Melanocytic nevi are extremely common benign tumors that mimic melanoma and are therefore commonly biopsied. Currently, the detection of melanoma is based on histological examination; however, disagreement between pathologists occurs in up to 10-25% of cases. Yet many indeterminate tumors are characterized by low cellularity and purity posing challenges to the currently available molecular technologies. Therefore, spatial genomics technologies for the detection of melanoma are needed to address many of these challenges. This presentation discusses a spatially resolved multiplex RNA analysis of 1,412 genes using formalin-fixed paraffin-embedded melanocytic tumors with the GeoMx™ Digital Spatial Profiler*

Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/)
2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/virtu....al-event/cell-biolog
3. Click Here to get your PACE credits (Expiration date – September 26, 2021 09:00 AM): https://www.labroots.com/credi....t/pace-credits/3554/

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc